Analyst Price Target Update on Quintiles Transitional Holdings (NYSE:Q)

Quintiles Transitional Holdings (NYSE:Q): 10 analysts have set the short term price target of Quintiles Transitional Holdings (NYSE:Q) at $75.05. The standard deviation of short term price target has been estimated at $6.26, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 83 and $62 respectively.

Many analysts have stated their opinion on the company shares. Brokerage firm Wells Fargo downgrades its rating on Quintiles Transitional Holdings (NYSE:Q). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 12, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP and COO) of Quintiles Transnational Holdings Inc., Gordon Kevin K had sold 24,000 shares worth of $1,593,840 in a transaction dated June 9, 2016. In this transaction, 24,000 shares were sold at $66.41 per share.

Quintiles Transitional Holdings (NYSE:Q) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.17 points or 0.26% at $65.4 with 1,529,941 shares getting traded. Post opening the session at $65.09, the shares hit an intraday low of $65.09 and an intraday high of $66.08 and the price was in this range throughout the day. The company has a market cap of $7,826 million and the number of outstanding shares have been calculated to be 119,668,196 shares. The 52-week high of Quintiles Transitional Holdings (NYSE:Q) is $80.45 and the 52-week low is $55.011.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *